Genprex, Inc. (GNPX)

NASDAQ: GNPX · IEX Real-Time Price · USD
2.710
-0.030 (-1.09%)
At close: Mar 27, 2024, 4:00 PM
2.610
-0.100 (-3.69%)
After-hours: Mar 27, 2024, 7:47 PM EDT

Company Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.

Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer.

The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.

Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Genprex, Inc.
Genprex logo
Country United States
Founded 2009
IPO Date Mar 29, 2018
Industry Biotechnology
Sector Healthcare
Employees 31
CEO John Rodney Varner

Contact Details

Address:
1601 Trinity Street, Bldg. B, Suite 3.322
Austin, Texas 78712
United States
Phone 512-537-7997
Website genprex.com

Stock Details

Ticker Symbol GNPX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001595248
CUSIP Number 372446104
ISIN Number US3724462037
Employer ID 90-0772347
SIC Code 2834

Key Executives

Name Position
John Rodney Varner Co-Founder, Chairman, President and Chief Executive Officer
Ryan M. Confer M.S. Chief Financial Officer
David M. Schloss Senior Vice President of Human Resources
Thomas C. Gallagher Esq. Senior Vice President of Intellectual Property and Licensing
Dr. Mark S. Berger M.D. Chief Medical Officer
Dr. Suzanne Thornton-Jones Senior Vice President of Regulatory Affairs and Quality
Dr. Jack A. Roth F.A.C.S., M.D. Chairman of Scientific and Medical Advisory Board

Latest SEC Filings

Date Type Title
Mar 20, 2024 424B5 Filing
Mar 20, 2024 8-K Current Report
Mar 6, 2024 8-K Current Report
Feb 26, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 5, 2024 8-K Current Report
Feb 2, 2024 8-K Current Report
Jan 31, 2024 8-K Current Report
Jan 5, 2024 8-K Current Report
Dec 18, 2023 8-K Current Report